UnicoCell (6794) reported revenue of NT$1.3 million for Oct 2026, -44.4% year on year and -48.7% from the previous month. Revenue for Jan–Oct 2026 was NT$18.6 million (-28.5% year on year).
In Oct 2026, it ranked No. 148 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$1.3 million | -44.4% | -48.7% |
| Sep 2026 | NT$2.5 million | +83.7% | +62.6% |
| Aug 2026 | NT$1.5 million | +74.4% | -36.5% |
| Jul 2026 | NT$2.4 million | -18.8% | +90.0% |
| Jun 2026 | NT$1.3 million | -43.0% | -10.5% |
| May 2026 | NT$1.4 million | +52.4% | -24.8% |
| Apr 2026 | NT$1.9 million | -65.5% | +1.3% |
| Mar 2026 | NT$1.9 million | -66.4% | -28.9% |
| Feb 2026 | NT$2.6 million | +186.2% | +47.8% |
| Jan 2026 | NT$1.8 million | -47.2% | -15.4% |
| Dec 2025 | NT$2.1 million | -65.2% | +8.4% |
| Nov 2025 | NT$1.9 million | -10.1% | -16.0% |
| Oct 2025 | NT$2.3 million | -11.8% | +69.5% |
| Sep 2025 | NT$1.4 million | -76.9% | +54.4% |
| Aug 2025 | NT$883,000 | -85.7% | -70.4% |
| Jul 2025 | NT$3 million | +14.8% | +33.3% |
| Jun 2025 | NT$2.2 million | +25.6% | +139.6% |
| May 2025 | NT$935,000 | +90.4% | -83.0% |
| Apr 2025 | NT$5.5 million | +284.2% | -1.1% |
| Mar 2025 | NT$5.6 million | +1,095.1% | +504.7% |
| Feb 2025 | NT$919,000 | +170.3% | -72.7% |
| Jan 2025 | NT$3.4 million | +81.0% | -44.3% |
| Dec 2024 | NT$6.1 million | +24.0% | +180.2% |
| Nov 2024 | NT$2.2 million | +1.2% | -17.6% |
| Oct 2024 | NT$2.6 million | +158.1% | -55.5% |
Jan–Oct 2026 cumulative: NT$18.6 million (-28.5% YoY)
Other Biotech & Medical companies
Compare with peers: UnicoCell vs PEC / UnicoCell vs Lotus Pharm / UnicoCell vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16